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The letter from Badve [1] relating to the series on pre-
invasive breast disease, published in the September and
November issues of Breast Cancer Research [2–10], is
timely and very welcome. It rightly points out that one
should be careful in changing classification systems
based on limited knowledge and that perhaps discarding
the term atypical ductal hyperplasia at the present time
may be premature. I completely agree with him; however,
there are a few issues I feel obliged to clarify.
Many of the authors writing in this series (Stuart Schnitt,
Hans Peterse, Sunil Lakhani, Ian Ellis) are also members of
the World Health Organisation panel involved in the ‘blue
book’ on classification of breast disease [11]. In this publi-
cation, the term atypical ductal hyperplasia has been
retained for exactly the reasons stated by Badve, and the
panel came to the consensus that at the present time dis-
carding the traditional classification was premature.
The series produced here is not a consensus statement.
They are a series of articles that is designed to educate
with regards to current thinking, difficulties and problems
of classification and evolving concepts as well as high-
lighting differences in practice. On behalf of the authors I
thank Badve for saying that ‘the articles are well written’,
but his criticism that the articles are in places contradic-
tory is misplaced since this was exactly the intention.
Finally, although I completely agree with the view that it
may be premature to discard the term atypical ductal
hyperplasia, the arguments he uses to justify this relating
to loss of heterozygosity analysis are incorrect. It is not
true that ‘two mutually contradictory conclusions can be
drawn from this [loss of heterozygosity analysis in pre-
invasive disease and normal tissues] data’. It is not simply
the presence or absence of loss of heterozygosity that
has been used to support the concept of multistep pro-
gression. It is the presence/absence of loss of heterozy-
gosity, the chromosomal regions involved, the frequency
of alterations, the morphological similarities and transi-
tions observed, and the data from a variety of molecular
studies supporting relationships between lesions that
have been used to construct a model of tumourigenesis.
It is not true that finding loss of heterozygosity in normal
tissues invalidates such a model and is therefore ‘of no
significance’. Badve is correct in stating that molecular
data should not be overinterpreted to support changing
the current classification systems, but by the same token
care should be exercised not to use the data out of
context to support an alternative view.
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